Eli Lilly has secured a significant victory in the fight against diabetes and obesity, with the U.S. Food and Drug Administration (FDA) approving Foundayo (orforglipron), a once-daily oral GLP-1 pill for chronic weight management in adults with obesity and overweight conditions. The approval, which came ahead of the anticipated April 10 Prescription Drug User Fee Act (PDUFA) date, has put Lilly on par with Novo Nordisk's Wegovy, which launched a weight-management injection earlier this year. The drug's approval has given Lilly a new tool in the growing market for GLP1 treatments, a category that is already a lucrative category in the drug industry. For example, Lilly plans to begin shipping foundayo shortly after the regulatory decisions, with initial shipments accepting immediately through LillyDirect and available through retail and retail pharmacies. The company also plans to make the pill accessible and affordable for those with insurance, with prices rising up to $349 per month for higher doses and those enrolled in Lilly’s Journey Program.